Expert Interview
Discussing ImmunoGen's drug Mirvetuximab Soravtansine in treating ovarian cancer
Ticker(s): IMGNInstitution: University of Toronto
- Professor and Chair of the division of Gynecologic Oncology at the University of Toronto, and Sunnybrook Health Sciences Center.
- Currently manages 200 patients with ovarian cancer.
- Interests and expertise include clinical trials, germ cell tumours, Gestational Trophoblastic Disease, Cervical Cancer (innovative surgical approaches, sentinel lymph nodes, and fertility sparing approaches), and Radical and Reconstructive Surgical Techniques in Gynecologic Oncology.
- Author of over 200 peer reviewed publications; Member of MAGIC a multidisciplinary multicooperative group team developing protocols in Malignant Germ Cell Tumours, and previous co-chair of the cervical cancer task force for the NCI (US).
Roughly how many patients with ovarian cancer do you currently manage?
Added By: c_admin
At a high level was was your impression of the SORAYA trial of Mirvetuximab Soravtansine?
Can you comment on the overall development program in Folate-receptor alpha high expressor subset, in context of previous failed FORWARD I phase 3 trial (2019)?
Added By: c_adminWhere do you anticipate mirvetuximab will be used if approved?
Added By: user6992bf87Do you anticipate any challenges with the adoption of folate-receptor alpha testing? If so, please describe.
Added By: user21373b6aAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
